- Home
- EML vs ACHV Comparison
EML vs ACHV Comparison
Compare EML & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | ACHV |
|---|---|---|
| Founded | 1858 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EML | ACHV |
|---|---|---|
| Price | $18.74 | $5.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 17.6K | ★ 569.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $18.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.49 | $1.84 |
| 52 Week High | $29.55 | $5.78 |
Technical Indicators
Market Signals| Indicator | EML | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 63.09 |
| Support Level | $18.98 | $4.30 |
| Resistance Level | $21.00 | $5.28 |
| Average True Range (ATR) | 0.70 | 0.26 |
| MACD | -0.10 | 0.07 |
| Stochastic Oscillator | 0.00 | 92.42 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.